The Cambridge, Massachusetts-based biotech priced 33.5 million shares at $20 each, topping the $625 million raised by Kailera Therapeutics in April

Patients in every other wealthy country already get the medications they need at prices their governments negotiated on their behalf.

Patients in every other wealthy country already get the medications they need at prices their governments negotiated on their behalf.

Bemotrizinol, long available in Europe, blocks both UVA and UVB rays and is cleared for adults and children 6 months and older